Coherus Oncology 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 net sales of Loktorzi were $14 million, up 3% quarter-over-quarter and 25% year-over-year; sequential growth was below the 10% to 15% target because of slower new patient starts in a few territories.
- Coherus had $83.6 million in cash, cash equivalents, and investments at the end of Q3 2026, compared with $105.3 million at the end of Q2, and used $34 million in cash in operations during Q3.
- Q3 2026 R&D expense from continuing operations was $22.6 million, down from $27.3 million in Q3 2025, while SG&A expense was $21.2 million, down from $24.9 million.
- Second-line esophageal cancer data at the 700 milligram tegmoquetuk dose with toropalmap showed 3 confirmed partial responses among 9 evaluable patients, a 33.3% confirmed overall response rate and a 44.4% confirmed plus unconfirmed overall response rate.
- In the first-line ESCC safety cohort, 8 of 9 efficacy-evaluable patients responded, for an 89% overall response rate; the response rate was 100% in PD-L1-positive patients and included 1 complete response.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead. Thank you, Heidi.
Third quarter earnings conference call. Joining me are Denny Lanfear, Chief Executive Officer of Coherus, Dr. Raj Diaz, Chief Medical Officer, Dr. Theresa LaVallee, Chief Scientific and Development Officer, Sameer Goregaoker, Chief Commercial Officer, and Bryan McMichael, Chief Financial Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus' current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly form on Form 10-Q for more information on risks and uncertainties. Now I'll turn the call over to Denny.
Thank you, Carrie, and good afternoon, everyone. Thank you for joining us on our third quarter 2026 earnings call. As you know, we have spent the last few years transforming Coherus from a biosimilars company into an innovative oncology company focused on overcoming immune resistance in cancer. We've made substantial progress in reducing our debt, lowering our OpEx, establishing LOQTORZI in the market, and advancing our clinical pipeline. We've conducted key clinical trials and developed sufficient data to set future development direction for our tagmokitug program and select the go-forward dose. Today, I will discuss three strategic alternatives designed to make Coherus a financially self-sustaining innovative oncology company with best-in-class and first-in-class products by the end of 2027. First, the strategic prioritization of esophageal cancer as our focus for best-in-disease with tagmokitug. Second, the structural and financial benefits that flow directly from this prioritization.
Finally, our emphasis on driving LOQTORZI revenues over the next four or five quarters to a level where they can fully support the company's core cash burn. When we launched the tagmokitug clinical program, it was with the clear expectation that we would select the most promising area for continued development. This is exactly what we have done. As we reported on October 28, over the last two years, we have explored a wide range of mucosal system cancers, from head and neck through esophageal, gastric, colorectal, across various lines of therapy to understand where Treg depletion might best be advanced as combination therapy. The emerging data from this very systematic clinical investigation demonstrated that esophageal cancer comprises a best-in-disease opportunity across first and second lines of therapy. Accordingly, going forward, we will sharply focusing our tagmokitug development efforts there, as this provides a substantial number of benefits.
First, providing a treatment alternative to patients confronting a particularly difficult cancer with poor prognosis. Second, our integrated approach across first and second-line therapy will seek FDA support for rapid, efficient, and affordable development path, leading to accelerated approval. Third, this enables ex-U.S. partnering. Our encouraging interim data in combination with toripalimab and our development efforts focused now enables partnering discussions for ex-U.S. rights. Toripalimab is approved in Europe and other regions for the treatment of ESCC irrespective of PD-L1 status, and it is being widely adopted in those markets. Esophageal cancer is the sixth in terms of annual cancer deaths globally, where over 400,000 patients are impacted annually, particularly in Asian countries. Our objectives for ex-U.S. partnering include, one, use of these upfront payments to offset clinical trial expenses and support the accelerated approval process.
Secondly, partner funding for ex-U.S. registration trials in their territories, significantly lowering the portion of overall cost that Coherus would need to incur. Third, leveraging the global regulatory constructs, such as FDA's Project Orbis, for harmonizing approvals across regions to the benefit of all parties. With data and clinical direction in hand, we are now engaging a financial advisor to conduct the tagmokitug partnering process, particularly with companies and countries with a high incidence of esophageal cancer. We will keep you informed on our progress. Now let me address the structural and financial benefits derived from our strategic prioritization of esophageal cancer. Over the last two or three years, we have pursued a broad development program across several cohorts, indications, more than 120 patients to identify the most promising indication of interest and the go-forward dose.
But these objectives have now been both met, with the dose and indication both identified for FDA discussions over 2027. At the same time, and somewhat fortuitously, two other concurrent events provide right-sizing and cost reduction opportunities for us. First, our process transfer of toripalimab from China to the U.S. is now complete as of Q3 2026, and the action date for the FDA for the drug product portion of the application is November 30th. You may recall the drug substance has already been approved earlier this year. This allows us to reduce the ongoing costs associated with this transfer and approval, which increased the burn over the last two years. Second, our transition services agreement with the acquirer of UDENYCA and Accord is now pretty much wound down, allowing us to further reduce our footprint across the company.
These TSA efforts were very labor-intensive for us and artificially inflated our cash burn and were confusing for investors. The confluence of these three events, strategic prioritization, wind-down of the TSA, and the imminent manufacturing transfer approval allows us an ideal opportunity to align and right-size our organization, consistent with the reduced scope of our efforts. Accordingly, we are announcing today that we are implementing projected 30% headcount reduction and attendant expense reductions. Our CFO, Bryan McMichael, will elaborate more on this in just a moment, but let me give you just one key metric so you can understand the benefits in context. These right-sizing and prioritizing reductions amount to $6 million-$7 million a quarter, which reduces the quarterly LOQTORZI revenues required to support the core burn from a previously guided $30 million-$35 million a quarter down to $25 million-$30 million a quarter.
This positions us to more readily establish a sustainable operating model, allowing us to continue investing in our high-value clinical opportunities with greater financial independence. Next, let me address commercial and revenues. Samir will provide more data directly, but I will just summarize here a few of the key growth drivers. While we continue to make steady progress in penetrating the NPC market, our current share is approximately only 20%-22%. This means that too many patients are still receiving inferior therapy, and this represents a key growth opportunity for us. Also, the relatively low market share results in quarter-to-quarter volatility and lumpiness when one of the regions gets a disproportionate number of patient fluctuations, such as discontinuations. This has to be addressed by increasing market share and penetration to damp out this.
There is substantial opportunity remaining, with about 30% of the patients continuing to receive chemotherapy alone and not benefiting from the LOQTORZI 6-year survival of 64.8 months versus 33.7 months with chemotherapy alone. Over the next year, we will need to dramatically reduce that 30% share by focusing on identifying these patients and reaching their providers, who can then prescribe LOQTORZI in combination with chemo, per our label. Given the compelling survival data, this objective appears reasonably within reach over the next 12 months. We also plan to address the 40% of the patients who are being treated with off-label immunotherapies that lack clinical evidence of efficacy. This share is steadily going down, but faster progress is needed here also. Physician reach and education are key here, so HCPs know that we have superior data versus chemotherapy alone in our standard of care.
Progress has been made here over the last three quarters, and Samir is going to tell you about that and our strategies to reach these physicians. Finally, our payer strategy is starting to bear fruit, as the step edits in place have proven very effective in modifying old prescribing behavior. They make physicians pay attention, so this is a successful strategy we are extending in 2027. With that, I will now turn the call over to Raj Diaz, M.D., our Chief Medical Officer.
Raj? Thank you, Denny. Today, I am going to talk to you about why we have selected esophageal cancer for future development as a best-in-disease approach.
We intend to pursue a second-line esophageal cancer study with both histologies, esophageal squamous cell and esophageal adenocarcinoma, as reported from our TREGCHECK 102 program due to, firstly, the strength of the signal. Secondly, the high unmet medical need, particularly in the second-line setting, where chemo alone is the current standard of care. Thirdly, the opportunity for a fast path to market strategy, leveraging FDA designations and development constructs. Let me start by addressing the second-line esophageal data and our plans. In this setting, we demonstrated activity in both squamous and adeno histologies at the go-forward dose of 700 milligrams tagmokitug with toripalimab. This includes nine evaluable second-line esophageal cancer patients, three adenocarcinomas and six squamous cell carcinomas.
The overall response rate data were very promising, as we saw three confirmed PRs plus one unconfirmed PR. That is a 33.3% confirmed ORR and a 44.4% unconfirmed plus confirmed ORR. This activity exceeded the chemo-only benchmark of around 10% ORR in this area of high unmet medical need. Additionally, the clinical benefit rate was 55.6%, with two patients remaining on treatment for over five months and two additional patients on treatment that have not as yet had their first tumor scan assessment. Importantly, this was a randomized study across the two doses, with 22 patients treated to date. For the 300 milligram tagmo dose in combination with tori, there were no responses, and all patients progressed by four months. This demonstrates two key findings. One, these data show that toripalimab in this second-line setting has limited activity, thereby establishing contribution of effect.
Second, it gives confidence in the tagmo go-forward dose of 700 milligrams, as it exhibits clear dose-dependent activity. Very importantly, both in terms of response and duration, activity was observed both in patients who are PD-1 refractory and also patients and tumors that are PD-L1 low or negative, meaning that tagmo-tori doublet both rescued PD-1 resistance and also demonstrated activity in cold or PD-L1 low or negative tumors. These data, irrespective of histology, inform next steps and provide the opportunity to progress our next study in second-line ESCC and second-line EAC, a similar approach that taken in the pembrolizumab phase III KEYNOTE-181 study. Our study will investigate the tagmo-tori doublet versus chemotherapy. Our immediate next step is to meet with the FDA to align on two topics. First, the recommended phase II dose to ensure we have satisfied the requirements of Project Optimus.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
